Ticker LaunchIPO · ELYM
Climb Bio, Inc.
Formerly Eliem Therapeutics, Inc.
Climb Bio, Inc. (ELYM) priced its initial public offering on Aug 11, 2021 at $12.50 per share, raising $80M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $317M. Cooley advised the company and Latham & Watkins advised the underwriters.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapies for neuronal excitability disorders, targeting chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. It aims to restore the balance between over-excited and inhibited neurons.
- Status
- IPO
- Ticker
- ELYM
- Exchange
- Nasdaq Global Market
- Priced
- Aug 11, 2021
- IPO price
- $12.50
- Raised
- $80M
- Market cap at IPO price
- $317M
- First filed
- Jul 16, 2021
- Company counsel
- Cooley
- Underwriters' counsel
- Latham & Watkins
- Sector
- Biotech & pharma
- Country / state
- MA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jul 16, 2021
- Latest amendment Aug 9, 2021
- Final prospectus (424B4) Aug 11, 2021
- All filings on EDGAR CIK 1768446
Other Biotech & pharma IPOs in 2021
- Dermata Therapeutics, Inc.DRMA · Aug 16, 2021 · $18M
- Invivyd, Inc.ADGI · Aug 6, 2021 · $309.4M
- Omega Therapeutics, Inc.OMGA · Aug 2, 2021 · $125.8M
- Rani Therapeutics Holdings, Inc.RANI · Aug 2, 2021 · $73.3M
- Icosavax, Inc.ICVX · Jul 30, 2021 · $182M
- Immuneering CorpIMRX · Jul 30, 2021